NMTR   $0.075  -42.34% Market Closed

9 Meters Biopharma Inc
Last Events:

2023-07-26 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-07-19 Signal in Stochastic changed from bearish to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-07-19 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-07-18 Trend pattern changed from расходящийся клин с наклоном вниз to нисходящий клин.

2023-07-18 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: down-crossing the middle level.

2023-07-18 Signal in EMA100 changed from n/a to bearish reversal. 2023-03-07 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

2023-05-20 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-05-18 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.


Current temperature: 2.10
ST: 0, Cor:

50-50 Year Forecast
Low with 51% probability: 0.04
Target: 0.75
High with 48% probability: 0.23
Analyst Recommendations:
Number of estimates 1
Target Price Mean 0.75
Mean unverified/preliminary 0.75 / 0.75
Target Price Low / High 0.75 / 0.75
Median / STD DEV 0.75 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - Sell -
stoch - Sell -
ma20 - Sell Sell
ma50 Sell - -
ma100 Sell Sell Sell
Candlestick PatternJuly 24, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US6544051096
ceo Ms. Bethany Sensenig C.M.A., M.B.A.
Website https://www.9meters.com
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina.